Replies to post #22898 on The Rising Influence of Rising Affluence

[DewDiligence]

CStone, PFE obtain China NMPA approval for PD-L1 agent, Cejemly (sugemalimab) in Stage III NSCLC; it was previously NMPA-approved in Stage IV (metastatic) NSCLC:

https://www.prnewswire.com/news-releases/cstone-and-pfizer-announce-nmpa-approval-of-sugemalimab-in-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer-301561552.html

Pursuant to a 2020 deal (#msg-158620042), PFE owns the commercial rights to Cejemly in Greater China and has a ~10% equity stake in CStone.